Luminopia Receives FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eye

Luminopia has received “de novo premarket” approval by the FDA for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the most common cause of vision loss in children.

Luminopia Receives FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eye
October 21, 2021
NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial

NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye).

NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial
March 11, 2022
Luminopia Receives $5.7M in Seed Extension Financing to Fund Amblyopia Treatment

Luminopia, a digital therapeutics company developing a new class of treatments for neuro-visual disorders, has secured an oversubscribed $5.7M seed extension financing round. The financing will be used by the company to offer its lead amblyopia treatment.

Luminopia Receives $5.7M in Seed Extension Financing to Fund Amblyopia Treatment
November 14, 2022
More